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Introduction
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma (NHL), accounts for ~30% of total NHLs. 1 While curable with R-CHOP treatment in the majority of DLBCL patients, up-to one third of those patients develop relapsed/refractory disease, a major cause of mortality and morbidity. 2, 3 DLBCL, a heterogeneous lymphoma, can be classified into major molecular subtypes (activated B-cell [ABC] and germinal center B-cell (GCB]) based on distinct gene expression and genetically mutational signatures. 4 Importantly, compared to GCB-DLBCL patients, the ABC population has lower survival rates following multi-agent chemotherapy. 5, 6 Since ABC-DLBCL is characterized by chronically active B-cell receptor (BCR) signaling, several components of BCR signaling pathways are emerging as attractive therapeutic targets. 4 Bruton's tyrosine kinase (BTK), the critical component of BCR signaling, drives the BCR signaling cascade leading to activation of NF-κB and other target signaling. 7, 8 Ibrutinib, an orally administered BTK inhibitor, has been FDA-approved to treat patients with relapsed mantle cell lymphoma, Waldenstrom's macroglobulinemia, and chronic lymphocytic leukemia, including those harboring the 17p deletion. 9, 10 In a phase I/II clinical trial of relapsed/refractory DLBCL, ibrutinib treatment resulted in an overall response rate of 37% in ABC-DLBCL patients versus 5% in GCB-DLBCL patients, indicating that the ABC subtype is more susceptible to BTK targeting. 4 Despite these encouraging results, responses to ibrutinib treatment are variable/incomplete and show drug-resistance and population/genetic alterations stemming from unknown causes. 11, 12 BCR signaling, initiated by self-antigen reactivity of BCR or by mutation in MYD88, activates both NF-κB in the ABC-DLBCL survival pathway and the phosphatidylinositol-3-kinase (PI3K) signaling pathway. 7, 13, 14 The class-I subPI3K family includes the alpha-, beta-, gamma-, and delta isoforms, which are often constitutively activated in cancer. 15 Koo et al reported that pan-PI3K inhibitors, which target all PI3K isoforms, exert a reduction in cell viability in a subset of ABC-DLBCL lines with CD79 mutations. 13 However, due to broad toxicities of pan-PI3K inhibitors, attention has shifted to use of single PI3K isoform specific inhibitors to treat cancer. 16 Idelalisib, a PI3K-delta specific inhibitor, received FDA approval for treatment of B-cell malignancies. [17] [18] [19] On the other hand, inhibition of PI3Kdelta in ABC-DLBCL cells led to activation of PI3K-alpha via a compensatory mechanism, defeating treatment intent. 20, 21 We have identified PI3K-beta/delta-mediated activation of AKT as a compensatory survival pathway that is potentially responsible for the emergence of ibrutinib-related resistance in ABC-DLBCL cells.
Treatment of ibrutinib resistant (IR) DLBCL cell lines with a selective dual PI3K-beta/delta inhibitor significantly reduced the AKT activity and tumor volume in xenografts. Moreover, when combined with currently used chemotherapeutic agents, the PI3K-beta/delta inhibitor strongly inhibited the growth of IR-DLBCL cells. This combination could provide an additional therapeutic strategy for overcoming ibrutinib resistance in DLCBLs.
Methods

Cell culture and drugs
ABC-DLBCL cell lines (TMD8, U2932, and HBL1) and GCB lines (SU-DHL-6 and SU-DHL-8) were maintained in RPMI-1640 media supplemented with 10% fetal bovine serum. OCI ABC and -GCB lines (OCI-LY1, OCI-LY3, OCI-LY7, OCI-LY8, and OCI-LY10) were maintained in Iscove's Modified Dulbecco's Medium with 20% human serum. All cell lines were regularly tested for mycoplasma and identity confirmation by Short Tandem Repeat. The BTK inhibitor ibrutinib (PCI-32765) and PI3K isoform specific inhibitors PI3K-alpha (alpelisib), PI3K-beta (AZD6482), PI3K-delta (idelalisib), and PI3K-alpha/delta (pictilisib) were purchased from Selleckchem. The PI3K-beta/delta dual inhibitor (KA2237) was provided by Karus Therapeutics Ltd. (Oxfordshire, UK).
Generation of IR ABC-DLBCL cell lines
IR-DLBCL cell lines (HBL1-Ib R , TMD8-Ib R , and OCI-LY10-Ib R ) were generated by continuously culturing parental lines (HBL1, TMD8, and OCI-LY10) with incremental doses of ibrutinib. The IC50s of the IR cell lines were 1200 nmol/L, 500 nmol/L, and 1740 nmol/L for OCI-LY10-Ib R , TMD8-Ib R , and HBL1-Ib R , respectively.
Stable knockdown of the PI3K-beta isoform in IR-DLBCL cells was performed using lentiviruses expressing human shRNA (Dharmacon; clone IDs V3LHS_341250 and 341251) as described previously. 22 
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Cell viability, colony formation, and apoptosis assay
To quantify surviving and/or proliferating cells, an MTT cell proliferation assay kit (Promega Corporation, Madison, WI, USA) was used according to the manufacturer's instructions. In each experiment, the average relative absorption (OD490-OD700) was used to estimate the number of metabolically active cells. The percent of treated cells that survived and normalized, compared to control cells, was calculated to evaluate cell viability. A colony formation assay was performed using a methylcellulose medium (H4100; STEMCELL Technologies Inc.) as described previously. 23 Synergistic combination indexes (CIs) between two drugs were calculated using MTT cell proliferation assays performed with combinations of different drug concentrations and using Calcusyn software. A CI value less than or equal to 0.8 indicates synergistic effects between two drug combinations.
For apoptosis assays, cells were washed with cold phosphate-buffered saline, fixed in 70% ethanol, and stained with a 0.5 µM propidium iodide solution (BD Pharmingen, BD Biosciences, San Jose, CA, USA). Propidium iodide staining was detected with flow cytometry (LSR Fortessa flow cytometer; BD Biosciences, San Jose, CA, USA), and the subG1 fraction was presented as the apoptotic population.
Xenograft study
Animal studies were completed under the Institutional Animal Care and Use Committee (IACUC)approved protocol for animal welfare at The MD Anderson Cancer Center, Houston, TX. Twenty-eight nude mice were subcutaneously injected with 5 X 10 6 OCI-LY10 cells (parental-or IR-DLBCL) in a suspension containing 1:1 Matrigel (Corning, Life Sciences). When the tumors reached approximately 300 mm 3 , mice in each group were randomly assigned (7 mice to each group) to treatment every other day by intraperitoneal injection with either KA2237 (100 mg/kg) or saline control. Tumor volumes (1/2 [length X width 2 ]) were measured thrice weekly.
Statistical analysis
Results were presented as means ± standard deviation of triplicates. Statistical analyses were carried out using the Student's t-test with P values less than 0.05 considered to be significant.
Results
Acquired ibrutinib resistance also enhances tumorigenic properties of ABC-DLBCL cells. To
understand the mechanism of ibrutinib resistance in DLBCL cells, we generated isogenic, resistant versions of 3 ABC-DLBCL cell lines (HBL1, TMD8, and OCI-LY10). The three lines were selected out of ten tested based on their sensitivity to ibrutinib (Online Supplementary Figure S1 A-C); note that all GCB-DLBCL cell lines examined in this study were resistant to ibrutinib. For these tests, the parental cell lines underwent in vitro culturing with incremental doses of ibrutinib ( Figure 1A and Online Supplementary Figure S1D ). Compared to parental cells, IR-DLBCL cells (HBL1-Ib R , TMD8-Ib R , and OCI-LY10-Ib R ) had higher proliferation rates ( Figure 1B ) and exhibited lower apoptosis signaling upon ibrutinib challenge (Online Supplementary Figure S1 E-F). Acquiring ibrutinib resistance was associated with increased colony number when plated in methylcellulose substrate ( Figure 1C ). Furthermore, we tested the tumorigenic potential of IR-DLBCL cells and found that those cells in nude mice xenografts had a higher tumor incidence and larger tumors compared to parental DLBCLs (parental, 9/14; IR, 14/14; P=0.04, Fisher's exact test) ( Figure 1D ), indicating that IR-DLBCL cells are clearly tumorigenic.
Cells with acquired resistance ibrutinib (IR-DLBCL) show upregulated PI3K/AKT/mTOR
signaling. We identified reduced BTK expression in cultured IR-DLBCL cell lines ( Figure 2A ) similar to the reduced BTK expression acquired by chronic lymphocytic leukemia patients following ibrutinib treatment. 24 BTK mutation C481S and others (e.g., PLCγ2) have been reported to be associated with ibrutinib resistance. 25, 26 However, in the IR-DLBCL cell lines examined in this study, targeted sequencing for BTK and PLCγ2 genes confirmed the lack of these mutations (data not shown). We anticipated that dysregulated signaling pathways could lead to development of ibrutinib resistance so we assayed the protein expression in our parental-and IR-DLBCL pairs by reverse phase protein array (RPPA). The RPPA data shown by heat maps ( Figure 2B ) revealed that 118 proteins were differentially expressed (±1.5-fold changes in expression). We observed the upregulation of DNA damage repair signaling molecules (CHK1, CHK2, and CDCD25C) in IR-DLBCL cells compared to parental cells; these results were further validated by Western blots (data not shown). However, treatment with CHK1 or CHK2 inhibitors alone or in combination with ibrutinib did not sensitize the IR-DLBCL cells (data not shown). From our RPPA data, we also identified enhanced PI3K/AKT/mTOR signaling in IR-DLBCL-an increase in expression of its activator IRS1 and a decrease in expression of its negative regulator PTEN. We further validated this activation of PI3K/AKT signaling by Western blot analyses of paired IR/parental DLBCL cells which confirmed enhanced levels of pAKT, p-mTOR, and the latter's substrate p-P70S6K in all three IR-DLBCL cell lines examined ( Figure 2C ).
Simultaneous inhibition of PI3K-beta and delta isoforms sensitized IR-DLBCL cells.
We identified upregulated PI3K/AKT/mTOR signaling in IR-DLBCL cells ( Figure 2 ), and then investigated how this signaling affects ibrutinib resistance. The PI3K pathway is constitutively deregulated in multiple malignancies; studies support the importance of PI3K signaling in leukemias and lymphomas. 15, 27 Loss of PTEN is a well-described mechanism of upregulation of PI3K/AKT/mTOR but loss of PTEN does not offer a practical restorative therapeutic option and thus we did not pursue this topic. 28 A previous study indicated the importance of PI3K signaling in the development of ibrutinib resistance in a patientderived xenograft model but a possible mechanism was not proposed. 29 A recent report of mantle cell lymphoma demonstrated that inhibition of the PI3K-alpha isoform in the tumor microenvironment overcame ibrutinib resistance. 30 Because pan-PI3K inhibitors might induce off-target cellular toxicity, we elected to examine the effects of various pharmacological inhibitors of PI3K with different isoform inhibition profiles. We first screened the expression levels of PI3K isoforms in our IR/parental DLBCL pairs; we observed a significant increase in the PI3K-alpha and -beta levels (~2-and 2.5-fold, respectively), a decrease in the PI3K-delta levels (~half-fold change), and no change in the PI3K-gamma levels ( Figure 3A ). We then hypothesized that enhanced PI3K-alpha or -beta isoform levels might be responsible for overall upregulated PI3K/AKT/mTOR signaling and the survival of our IR-DLBCL cells. Therefore, we treated those cells with PI3K isoform-specific inhibitors and found that PI3K-alpha (alpelisib), -beta (AZD6482), and -delta (idelalisib) responded marginally as single agents in an MTT cell proliferation assay and that they triggered no significant changes to pAKT levels (Figure 3 B-C).
We speculated that the lack of effect with these single inhibitors might be due to secondary compensatory mechanisms or feedback effects through activation of other PI3K isoforms, since a previous report noted that inhibition of PI3K-delta caused feedback activation of PI3K-alpha in the ABC subtype of DLBCL. 21 After treatment with a dual PI3K-alpha/delta inhibitor (pictlisib), our IR-DLBCL model did not show significant changes in pAKT levels or sensitization (Figure 3 B-C). However, treatment with the selective dual PI3K-beta/delta inhibitor KA2237 significantly reduced IR-DLBCL viability and blocked the activation of the AKT/mTOR axis ( Figure 3D ) suggesting that PI3K-beta and -delta are the key nodes with AKT/mTOR axis signaling and cell survival in IR-DLBCL.
Targeting the PI3K-beta isoform sensitized IR-DLBCL cells to a PI3K-delta inhibitor. To understand the potential role of the PI3K-beta isoform in the development of ibrutinib resistance, we performed a stable knockdown of that isoform in our IR-DLBCL cells using two independent shRNAs; neither caused changes in expression of other PI3K isoforms ( Figure 4A ). We noted that the PI3K-betaisoform knockdown did not alter the colonogenic ability or cell growth rate of IR-DLBCL cells (data not shown). PI3K-beta knockdown did not change the activity of the AKT/mTOR axis ( Figure 4C ) nor did it sensitize cells to ibrutinib (data not shown). However, consistent with our results using a PI3Kbeta/delta dual inhibitor (Figure 3) , treatment of the PI3K-beta-knockdown cells with the PI3K-delta inhibitor idelalisib uniformly reduced the growth rates of IR-DLBCL cells ( Figure 4B ) and significantly reduced AKT/mTOR activity in all three IR-DLBCL cell lines (Figure 4 B-C) suggesting a PI3K-deltamediated activation of compensatory survival signaling in PI3K-beta-knockdown IR-DLBCL cells. We further treated IR-DLBCL cells with PI3K-beta and -delta specific inhibitors administered separately and in combination. Treatment with either agent alone did not reduce cellular viability, but when combined, the treatments acted synergistically and significantly reduced cellular viability ( Figure 4D and Online Supplementary Figure S2 and Table S1 ). In both cell types, the loss of cell viability was preceded by reduced pAKT levels (data not shown).
Combining a PI3K-beta/delta dual inhibitor with chemotherapeutic agents sensitized IR-DLBCL
cells.
Given the potent activity of the selective dual PI3K-beta/delta inhibitor KA2237, we explored its effects on tumorigenic properties. As a single agent, KA2237 exerted a robust reduction in the colonyformation ability of our IR-DLBCL cells ( Figure 5A and Online Supplementary Figure S3A) ; and in a xenograft model, the agent (100mg/kg, intraperitoneal, every other day) inhibited the growth of OCI-LY10-Ib R DLBCL tumors ( Figure 5B ). Analysis of tumor extracts showed that KA2237 significantly reduced pAKT levels and concomitantly decreased mTOR activity ( Figure 5C ). We then explored the potential therapeutic application of this PI3K-beta/delta inhibitor when used with standard DLBCL chemotherapeutic agents. We treated our IR-DLBCL cells with KA2237 in combination with each of three such agents (doxorubicin, vincristine, or vorinostat) and observed synergy (Online Supplementary   Table S2 ) and a significant reduction in cell growth ( Figure 5D and Online Supplementary Figure S3B ). 10 
Discussion
Aggressive lymphomas such as ABC-DLBCL are a major cause of morbidity and mortality, primarily due to the development of therapeutic resistance. 6 Chronic activation of BCR signaling by BTK provides survival benefits to ABC-DLBCL cells; thus, BCR signaling remains an important therapeutic target for patients who are refractory to, or have relapsed from, current R-CHOP chemotherapy. 31, 32 The FDA-approved BTK inhibitor ibrutinib has shown significant efficacy in treating ABC-DLBCL patients; however ibrutinib resistance frequently follows. 7, 11, 32 Using lines examined in this study, we discovered that ibrutinib-resistance is acquired through compensatory activation of PI3K/AKT/mTOR signaling, which supports survival and enhances the tumorigenic properties in these IR ABC-DLBCLs.
Furthermore, we found that PI3K/AKT signaling is maintained in our IR-DLBCL cell lines through the PI3K-beta and delta isoforms. We confirmed the dependency of these IR ABC-DLBCL cells on the PI3K-beta/delta subunits by knocking down the PI3K-beta isoform in acquired IR-DLBCL cell lines and by inhibiting the PI3K-beta/delta isoforms that effectively blocked PI3K/AKT signaling and induced death of IR-DLBCL cells.
Previous reports suggest that patients who are nonresponsive to ibrutinib may often have mutations in BTK (BTKC481S) and/or PLCγ2 (R665W,L845F,S707Y). 33 However, our targeted sequencing of three IR-DLBCL cell lines identified no such genetic alterations in these two genes (data not shown) suggesting that the selection of mutant clones during generation of IR lines is not a cause/mechanism of acquired resistance. Another study confirmed the role of mutant MYD88 expression in providing partial resistance to ibrutinib in ABC-DLBCL cell lines. 34 We observed the overexpression of BCL2 and inhibitor-of-apoptosis family members (cIAP, xIAP, and survivin) in our IR-DLBCLs cells (Online Supplementary Figure S1F ). This is consistent with a previous report that identified elevated BCL2 expression following development of ibrutinib resistance. 35 While venetoclax, an FDA-approved BCL2 inhibitor, can promote anti-proliferative activity for IR-DLBCL, targeting BCL2 could lead to the development of resistance to a BCL2-inhibitor. As an example, one study showed that either short-or long-term exposure of B-cell lymphoma cell lines (MCL and DLBCL) to venetoclax led to the development of venetoclax resistance due to a reduction in PTEN expression (a negative regulator of the PI3K/AKT activation pathway). 36 Our RPPA analysis from three IR cell lines showed a significant decrease in PTEN expression with enhanced expression of activated AKT (p-AKT) and downstream activation of mTOR signaling, suggesting the critical role of PI3K signaling in survival of acquired IR-DLBCLs ( Figure 2C ).
Given the high frequency of PI3K-pathway activation in human cancers, several PI3K inhibitors are being tested in clinical trials. This includes pan-PI3K inhibitors, which demonstrate great efficacy but also produce adverse toxicity effects. 16 As such, selective PI3K isoform specific inhibitors are of interest. The PI3K-delta specific inhibitor idelalisib was approved by the FDA for treating relapsed chronic lymphocytic leukemias and B-cell lymphomas, yet the drug has not provided significant improvement in overall survival. 19, [37] [38] [39] Multiple studies have revealed the feedback activation of PI3K pathways or compensatory effects among various PI3K isoforms in response to PI3K inhibitors. For example, activation of PI3K-beta isoform was identified in preclinical studies after PI3K-alpha was blocked. [40] [41] [42] Therefore, targeting multiple PI3K isoforms with dual PI3K-isoform specific inhibitors might eliminate compensatory/feedback responses caused by targeting single PI3K-isoform selective drugs. In support, one study showed tumor regression using a PI3K-alpha/delta dual inhibitor (copanlisib) in CD79B(WT)/MYD88(mut) patient-derived IR ABC-DLBCL cells, underscoring a genetic mechanism of ibrutinib resistance regulated by PI3K isoforms. 20 Our acquired IR-DLBCL model did not show significant changes in pAKT levels or sensitization after treatment with a dual PI3K-alpha/delta inhibitor (pictlisib) even though we observed a significant increase in the PI3K-alpha isoform (Figure 3 B-C) . We speculated that this was due to differential activation of the signaling pathways between the derived genetic mutations and the chronically-exposed, acquired-IR model. Along with an increase in PI3K-alpha expression, we identified a strong and significant increase in expression of the PI3K-beta isoform in our acquired IR-DLBCL model ( Figure 3A) . Treatment with the single PI3K-beta specific inhibitor (AZD6482) did not alter the pAKT level nor kill the IR-DLBCL cells (Figure 3 B-C) ; whereas, treatment with a PI3K-beta/delta dual inhibitor (KA2237) significantly reduced AKT/mTOR signaling and profoundly reduced IR xenograft tumors (Figures 3 and 5 ). To note, we also observed reduced expression of the PI3K-delta isoform in IR-DLBCL cells compared to parental cells, suggesting that even modest expression of the delta isoform might be mediating feedback activation of PI3K signaling in IR-DLBCL cells. After knocking down a PI3K-beta isoform and treating it with a PI3K-delta isoform inhibitor, we confirmed that PI3K-beta and -delta isoforms were involved in maintaining ibrutinib resistance in ABC-DLBCL cells (Figure 4) . These results suggest that enhanced PI3K-beta expression might be masking the effect of the PI3K-delta inhibitor in IR lines. We observed a reduction in the PI3K-beta isoform (without expression changes in other PI3K isoforms) following treatment with the PI3K-beta/delta inhibitor KA2237 in IR cells (data not shown). This, further supports our hypothesis that enhanced expression of the PI3K-beta isoform might reduce the anti-proliferative activity of the PI3K-delta specific inhibitor in IR lines. We further substantiated our ibrutinib findings using a second targeting agent, ACP-196, a more selective inhibitor of BTK. 43 We generated an ACP-196-resistant model of two ABC-DLBCL cell lines (TMD8 and OCI-LY10) and observed upregulation of PI3K/AKT/mTOR signaling, with sensitization of ACP-196 resistant DLBCL cells after challenge with the PI3K-beta/delta dual inhibitor (data not shown).
In summary, our results show that after gaining ibrutinib resistance, ABC-DLBCL cells have reduced expression of BTK and are dependent on PI3K/AKT/mTOR signaling for their survival. We found that upregulation of the PI3K/AKT axis was due to an increased expression of the PI3K-beta isoform, which masked the sensitization of cells to a PI3K-delta inhibitor. Targeting the PI3K/AKT/mTOR axis with a PI3K-beta/delta selective inhibitor reduced both tumorigenic properties and survival-based PI3K/AKT/mTOR signaling of ibrutinib-resistant cells. These effects were enhanced when combined with chemotherapeutic agents active against DLBCL ( Figure 5E ).
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